Back to top

Analyst Blog

Idenix Pharmaceuticals, Inc. recently announced that it has initiated a phase II study (HELIX-1: n = 90) evaluating the combination of hepatitis C virus (HCV) infection candidates, samatasvir (IDX719) and simeprevir (TMC435). The study is being conducted in collaboration with Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson (JNJ - Analyst Report).

As monotherapy, samatasvir is being developed by Idenix Pharma and simeprevir by Johnson & Johnson in collaboration with Medivir AB.

The 12-week, randomized, double-blind and parallel group HELIX-1 study will evaluate three doses of samatasvir (50, 100, or 150 mg). The study will assess the safety and tolerability of samatasvir in combination with simeprevir and ribavirin, a widely used HCV infection drug in first-line non-cirrhotic, genotype 1b or 4 HCV-infected patients.

We remind investors that Idenix Pharma entered into a non-exclusive collaboration agreement with Johnson & Johnson, in Jan 2013, to develop HCV combination therapies. The collaboration will assess different combinations of samatasvir, simeprevir, and TMC647055 (another Johnson & Johnson’s HCV candidate).

As per the terms of the agreement, Idenix Pharma will conduct the studies, while Johnson & Johnson will supply simeprevir and TMC647055 for the trials free of cost.  Both the companies will not receive any milestone and royalty payments as a part of the agreement.

Idenix Pharma plans to initiate a second phase II trial (HELIX-2) on samatasvir, simeprevir and TMC647055 in the second half of 2013.

A sizeable population suffers from HCV the world over. However, the treated population is much lower. This leaves the field open for new treatments.

Both Idenix Pharma and Johnson & Johnson, currently carry a Zacks Rank #3 (Hold). Right now, companies that look well-positioned include Zacks Ranked #1 (Strong Buy) Jazz Pharmaceuticals (JAZZ - Analyst Report) and Salix Pharmaceuticals, Ltd. (SLXP - Analyst Report).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%